The Switzerland-based drug giant Novartis AG (ADR) (NYSE:NVS) has reached another milestone with the latest patent litigation settlement in the U.S. The company reached a settlement with the U.S. subsidiary of Sun Pharmaceutical Industries. The agreement touches on the development of a generic version of Gleevec, a patented prescription drug whose patent protection expires in 2019. The settlement permits the subsidiary of Sun Pharmaceutical to develop and market a generic version of Gleevec. Novartis AG (ADR) (NYSE:NVS) net profit margin is 16.50% and weekly performance is 1.66%. On last trading day company shares ended up $89.88. Analysts mean target price for the company is $87.94. Novartis AG (ADR) (NYSE:NVS) distance from 50-day simple moving average (SMA50) is 6.37%.
Celgene Corporation (NASDAQ:CELG) announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $2,500 million. Of these notes, $500 million will mature in 2019 and will bear interest at an annual rate of 2.250 percent; $1,000 million will mature in 2024 and will bear interest at an annual rate of 3.625 percent and $1,000 million will mature in 2044 and will bear interest at an annual rate of 4.625 percent. The 2.250 percent notes due 2019, the 3.625 percent notes due 2024 and the 4.625 percent notes due in 2044 were priced to yield 2.303 percent, 3.666 percent and 4.647 percent, respectively. Celgene Corporation (NASDAQ:CELG) shares fell -1.03% in last trading session and ended the day on $147.32. Gross Margin is 94.90% and its return on assets is 10.70%. Celgene Corporation (NASDAQ:CELG) quarterly performance is -10.13%.
Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) lost a bid to block approval of a generic form of Copaxone, a multiple sclerosis drug that may account for half the company’s profit, 10 days before the patent on the medication expires. Teva’s lawsuit, accusing the Food and Drug Administration of improperly dismissing its calls for more testing of generic forms of Copaxone before they go on the U.S. market, was thrown out yesterday by a federal judge in Washington. Copaxone, the company’s bestselling drug, contributes more than 50 percent of earnings, according to analysts. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares moved up 0.07% in last trading session and was closed at $49.81, while trading in range of $49.28 – $50.00. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) year to date (YTD) performance is 26.07%.
AAON Inc (NASDAQ:AAON) announced a semiannual dividend on Monday, May 5th, ARN reports. Stockholders of record on Thursday, June 12th will be paid a dividend of 0.13 per share on Tuesday, July 1st. This represents a dividend yield of 0.82%. The ex-dividend date is Tuesday, June 10th. This is a boost from AAON’s previous semiannual dividend of $0.10. AAON, Inc. (NASDAQ:AAON) ended the last trading day at $30.28. Company weekly volatility is calculated as 3.59% and price to cash ratio as 30.55. AAON, Inc. (NASDAQ:AAON) showed a negative weekly performance of -1.53%.
On May 5, Mid-Con Energy Partners, LP (Nasdaq:MCEP) announced operating and financial results for the first quarter ended March 31, 2014. Increased production 3% sequentially and 4% year-over-year to an average of 2,622 barrels of oil equivalent per day (“Boe/d”) during the first quarter of 2014; Recorded Adjusted EBITDA of $12.7 million in the first quarter of 2014, versus $14.4 million in the fourth quarter of 2013 and $14.6 million in the first quarter of 2013. Mid-Con Energy Partners LP (NASDAQ:MCEP) net profit margin is 34.50% and weekly performance is 1.63%. On last trading day company shares ended up $21.78. Analysts mean target price for the company is $26.00. Mid-Con Energy Partners LP (NASDAQ:MCEP) distance from 50-day simple moving average (SMA50) is -0.81%.
Leave a Reply